QUEENSBURY, N.Y., Dec 10, 2004 (BUSINESS WIRE) -- AngioDynamics, Inc. (NASDAQ:ANGO) today announced its release of the EvenMore^™ chronic hemodialysis catheter. Designed for long-term use in dialysis patients, the EvenMore catheter is now being offered throughout the United States.

The EvenMore chronic hemodialysis catheter is a non-position dependent, 14.5 French end-hole design catheter. Offering less than five percent recirculation, the catheter's low profile lumen-to-wall ratio is designed to deliver high flow. The catheter also features a Durathane^™ shaft -- a biocompatible and durable material that offers high chemical resistance, which helps simplify site care since the material can be cleaned with either iodine or alcohol.

AngioDynamics will be providing the EvenMore catheter in a kit that includes the EmboSafe^™ Valved Splittable Sheath dilator, a sheath designed to reduce the risk of blood loss and air intake while allowing for smooth catheter insertion.

Commenting for AngioDynamics, Don Geer, Director, Vascular Access Products, said, "AngioDynamics is taking a value added approach with the EvenMore kit. By offering a choice of catheter size along with the EmboSafe valved splittable sheath dilator and other components that work directly with the catheter, the Company is providing one-stop shopping for the physician. This product is a reflection of our continued dedication to growing our hemodialysis product line to meet physicians' needs."

For additional information on the EvenMore catheter and kit, contact Don Geer at 1-800-772-6446, ext. 167, Email: dgeer@angiodynamics.com or visit the AngioDynamics web site at www.angiodynamics.com.

About AngioDynamics

AngioDynamics, Inc. (www.angiodynamics.com) designs, develops, manufactures and markets innovative medical devices used in minimally invasive, image-guided procedures to treat peripheral vascular disease. It offers a broad line of therapeutic and diagnostic devices that enable interventional physicians, such as interventional radiologists, vascular surgeons and others, to treat peripheral vascular diseases and other non-coronary diseases. AngioDynamics' diversified product line includes angiographic catheters, hemodialysis catheters, PTA dilation catheters, thrombolytic products, image-guided vascular access products, endovascular laser venous system products, as well as drainage products.

The statements made in this document contain certain forward-looking statements. Words such as "expects", "intends", "anticipates", "plans", "believes", "seeks", "estimates," or variations of such words and similar expressions, are intended to identify such forward-looking statements. The statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties or other factors that may cause the Company's actual results, levels of activity, performance or achievements to be materially different than expressed or implied by the forward-looking statements. These risk factors include the ability of the Company to develop its products, market acceptance and future sales of the EvenMore^™ chronic hemodialysis catheter, future actions by the FDA or other regulatory agencies, results of pending or future clinical trials, overall economic conditions, general market conditions, foreign currency exchange rate fluctuations, and competition, as well as the risk factors listed from time to time in the SEC filings of AngioDynamics Inc., including its Form 10-K for the year ended May 29, 2004.

SOURCE: AngioDynamics, Inc.

AngioDynamics, Inc.
Don Geer, 800-772-6446 ext. 167
http://www.angiodynamics.com
or
Lippert/Heilshorn & Associates, Inc. (Investor Relations)
Kim Sutton Golodetz, 212-838-3777
kgolodetz@lhai.com
Bruce Voss, 310-691-7100
bvoss@lhai.com